BioAlliance Pharma announced it has received marketing authorization from the FDA for Sitavig (acyclovir) in the treatment of recurring Herpes labialis. Sitavig is a nucleoside analog that comes in the form of a mucoadhesive tablet.
Utilizing the proprietary Lauriad technology, Sitavig delivers a high concentration of acyclovir directly to the lip, the site of the cold sore infection. Based on the results of a Phase 3 international study (n=775), Sitavig demonstrated a high level of efficacy in terms of healing time with one single tablet.
Sitavig will be available as a 50mg mucoadhesive tablet.
For more information visit www.bioalliancepharma.com.